4.5 Article

Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes

期刊

ANNALS OF HEMATOLOGY
卷 101, 期 3, 页码 557-569

出版社

SPRINGER
DOI: 10.1007/s00277-021-04734-2

关键词

Safety; SIRP alpha; IgG4PE; Macrophages; Hematological cancer

资金

  1. Celgene, a Bristol Myers Squibb Company
  2. National Cancer Institute of the National Institutes of Health [P30 CA016359]
  3. Bristol-Myers Squibb
  4. National Institutes of Health [P30 CA016359]

向作者/读者索取更多资源

Y CC-90002 is an anti-CD47 antibody that inhibits CD47-SIRP alpha interaction and enables macrophage-mediated killing of tumor cells in hematological cancer cell lines. The phase 1 clinical trial in patients with relapsed/refractory AML or high-risk MDS showed that CC-90002 led to mostly adverse events such as diarrhea and thrombocytopenia, with no objective responses observed. Further studies are needed to understand the lack of monotherapy activity and the development of anti-drug antibodies in this treatment.
Y CC-90002 is an anti-CD47 antibody that inhibits CD47-SIRP alpha interaction and enables macrophage-mediated killing of tumor cells in hematological cancer cell lines. In this first clinical, phase 1, dose-escalation and -expansion study (CC-90002-AML-001; NCT02641002), we evaluated CC-90002 in patients with relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). CC-90002 was administered in escalating doses of 0.1-4.0 mg/kg, using a modified 3 + 3 design. Primary endpoints included dose-limiting toxicities (DLTs), non-tolerated dose (NTD), maximum tolerated dose (MTD), and recommended phase 2 dose. Secondary endpoints included preliminary efficacy, pharmacokinetics, and presence/frequency of anti-drug antibodies (ADAs). Between March 2016 and July 2018, 28 patients were enrolled (24 with AML and 4 with MDS) at 6 sites across the USA. As of July 18, 2018, all patients had discontinued, mainly due to death or progressive disease. The most common treatment-emergent adverse events were diarrhea (46.4%), thrombocytopenia (39.3%), febrile neutropenia (35.7%), and aspartate aminotransferase increase (35.7%). Four patients experienced DLTs (1 patient had grade 4 disseminated intravascular coagulation and grade 5 cerebral hemorrhage, 1 had grade 3 purpura, 1 had grade 4 congestive cardiac failure and grade 5 acute respiratory failure, and another had grade 5 sepsis). The NTD and MTD were not reached. No objective responses occurred. CC-90002 serum exposure was dose-dependent. ADAs were present across all doses, and the proportion of ADA-positive patients in cycle 1 increased over time. Despite no unexpected safety findings, the CC-90002-AML-001 study was discontinued in dose escalation for lack of monotherapy activity and evidence of ADAs. However, as other anti-CD47 agents in clinical trials are showing promising early results for AML and MDS, understanding preclinical and clinical differences between individual agents in this class will be of high importance.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据